# Evaluation of the Efficacy and Safety of Lubiprostone in Adults With Mixed or Unsubtyped Irritable Bowel Syndrome

> **NCT02544152** · PHASE2 · TERMINATED · sponsor: **Sucampo Pharma Americas, LLC** · enrollment: 71 (actual)

## Conditions studied

- Irritable Bowel Syndrome

## Interventions

- **DRUG:** Lubiprostone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02544152
- **Lead sponsor:** Sucampo Pharma Americas, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-02
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2019-12-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02544152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02544152, "Evaluation of the Efficacy and Safety of Lubiprostone in Adults With Mixed or Unsubtyped Irritable Bowel Syndrome". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02544152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*